Tirzepatide: Evidence, Mechanism & Approved Uses

Tirzepatide holds two distinct FDA approvals under separate brand names, each covering a specific indication.

Mounjaro (tirzepatide) received FDA approval in May 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. This approval was based on the five-trial SURPASS clinical development program. It is a prescription medication for adults with confirmed type 2 diabetes. It is not approved for weight management under the Mounjaro label.

Zepbound (tirzepatide) received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. This approval was based on the SURMOUNT program. In December 2024, the FDA expanded the Zepbound indication to include a specific approval for moderate-to-severe obstructive sleep apnea in adults with obesity, based on two randomized, double-blind, placebo-controlled studies (SURMOUNT-OSA).

Both approvals require use alongside reduced-calorie eating and increased physical activity — tirzepatide is not approved as a standalone intervention separate from behavioral changes.

Uses outside these approved indications — including applications in polycystic ovary syndrome, non-alcoholic (metabolic dysfunction-associated) steatohepatitis (MASH), heart failure with preserved ejection fraction, and other conditions — are off-label or investigational. Active clinical trials are evaluating several of these applications, but they do not carry FDA approval as of this writing (2026) and should not be characterized as established uses.

Tirzepatide is a synthetic 39-amino-acid acylated peptide designed as a unimolecular dual agonist at two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Both receptors are expressed in pancreatic beta cells, where simultaneous stimulation produces coordinated increases in glucose-dependent insulin secretion — meaning the insulin-releasing effect only occurs when blood glucose is elevated, which is why the risk of hypoglycemia with tirzepatide alone is low.

At the GLP-1 receptor, tirzepatide reproduces the core incretin effects of native GLP-1: it slows gastric emptying (blunting post-meal glucose excursions), suppresses glucagon secretion in a glucose-dependent manner, and acts on appetite-regulating circuits in the hypothalamus and brainstem to reduce food intake and promote satiety. These central effects operate through direct action on area postrema and nucleus tractus solitarius neurons and through vagal afferent signaling from the gut.

At the GIP receptor, tirzepatide adds metabolic effects that GLP-1-only agents do not produce. In adipose tissue, GIPR agonism cooperates with insulin to enhance glucose uptake and improve lipid clearance in the fed state, while supporting lipolysis in the fasted state. This context-dependent adipocyte regulation may contribute to fat mass reduction beyond what weight loss alone would predict. In the central nervous system, GIP receptors in the ventromedial hypothalamus appear to contribute independently to appetite suppression — additive to the GLP-1 signal.

The molecule is also engineered with a C20 fatty diacid moiety enabling albumin binding, which extends the half-life to approximately five days and supports subcutaneous dosing on an extended schedule. Published structural work (Coskun et al., JCI Insight 2020, grounding this characterization) identified that tirzepatide acts as a biased agonist at GLP-1R, preferentially coupling to the cAMP/Gs pathway over the beta-arrestin pathway — a design feature thought to reduce receptor internalization and contribute to tolerability.

The SURPASS program comprised five Phase 3 randomized controlled trials (RCTs) that formed the basis for the Mounjaro approval. Evidence tier: strong (pivotal Phase 3 RCTs, FDA label).

SURPASS-1 (Lancet, 2021; n=478, 40-week monotherapy, placebo-controlled) established the glycemic efficacy signal: all tirzepatide trial arms reduced HbA1c by 1.87% to 2.07% from baseline, compared with a +0.04% change in the placebo group. Up to 92% of tirzepatide participants reached the ADA target of HbA1c below 7%, and up to 52% reached normoglycemic HbA1c below 5.7%. These rates of glycemic normalization were unusually high among glucose-lowering trials.

SURPASS-2 (NEJM, 2021; n=1,879, 40 weeks) was an active-comparator trial against a then-standard diabetes dose of semaglutide. Tirzepatide at the highest trial arm reduced HbA1c by 2.30% and body weight by 11.2 kg, both significantly greater than the semaglutide comparator arm (1.86% HbA1c reduction; 5.7 kg weight reduction). This was a first published head-to-head trial establishing superiority over an established GLP-1 mono-agonist.

The SURPASS cardiovascular outcomes trial (completed 2024; n over 12,000, approximately 4-year median follow-up) compared tirzepatide with dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The primary endpoint — a composite of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) — occurred in 12.2% of the tirzepatide group versus 13.1% of the dulaglutide group, meeting the non-inferiority threshold. The tirzepatide arm also demonstrated greater body weight reduction (11.6% vs 4.5%, a 7.1 percentage-point difference), a meaningful secondary finding.

These trials collectively support the approved use claim that tirzepatide improves glycemic control in type 2 diabetes across diverse background medication regimens and prior treatment histories.

The SURMOUNT program tested tirzepatide specifically for obesity and overweight with comorbidities, forming the evidence base for the Zepbound approval. Evidence tier: strong (pivotal Phase 3 RCTs, FDA label).

SURMOUNT-1 (NEJM, 2022; n=2,539, 72 weeks, placebo-controlled) enrolled adults with obesity without diabetes — a pure weight management population. Mean body weight reductions across tirzepatide trial arms were 16.0%, 21.4%, and 22.5% from baseline, compared with 2.4% for placebo. These were among the largest weight-loss magnitudes reported in any Phase 3 pharmaceutical trial up to that point. Approximately 37% of participants at the highest trial arm lost more than 25% of body weight.

SURMOUNT-5 (completed 2025) was the first head-to-head Phase 3 RCT directly comparing tirzepatide with the FDA-approved weight management dose of semaglutide. Over 72 weeks, tirzepatide produced a mean weight change of approximately 20.2% versus 13.7% for semaglutide, a difference of roughly 6.5 percentage points confirming the superiority signal seen in SURPASS-2 in a pure-obesity population.

SURMOUNT-OSA ran two randomized, double-blind, placebo-controlled 52-week Phase 3 trials in adults with moderate-to-severe obstructive sleep apnea and obesity. Tirzepatide at the highest trial arm significantly reduced the apnea-hypopnea index (a measure of sleep apnea severity), with reductions of approximately 27 events per hour in CPAP users and 25 events per hour in non-CPAP users — accompanied by improvements in hypoxic burden and patient-reported sleep quality. This data supported the December 2024 FDA indication expansion specifically for obstructive sleep apnea in adults with obesity.

A prediabetes sub-analysis of SURMOUNT-1 (2025 post-hoc publication) found that among the roughly 1,000 participants with prediabetes at baseline, tirzepatide showed low rates of progression to type 2 diabetes during the treatment period, with regression to normoglycemia in the majority. Over 60% of the glycemic improvement was estimated to be attributable to mechanisms beyond weight loss alone, consistent with the direct receptor-mediated metabolic effects discussed in the mechanism section. This finding is not a separate approved indication — it is a secondary observation from within an already approved population.

This distinction matters clinically because GLP-1 mono-agonists (semaglutide, liraglutide, dulaglutide, exenatide) and tirzepatide are often grouped together as the same drug class in popular discussion, but the mechanistic and efficacy differences are meaningful.

The core pharmacological difference is receptor targeting. GLP-1 mono-agonists activate only the GLP-1 receptor. Tirzepatide activates both the GLP-1 receptor and the GIP receptor with full agonism at GIPR. This is not a modest add-on — GIP and GLP-1 together produce synergistic effects on insulin secretion that exceed what either receptor could produce alone in an additive model.

The efficacy gap in weight loss is the most clinically striking difference. In the SURPASS-2 active-comparator trial, tirzepatide produced roughly twice the weight loss of the semaglutide comparator arm (11.2 kg vs 5.7 kg over 40 weeks). SURMOUNT-5 confirmed a 6.5 percentage-point advantage over the comparator arm in a pure-obesity population. These differences are large enough to be clinically meaningful — a 6.5% relative difference in body weight represents a substantial absolute mass reduction at baseline weights typical of trial populations.

The glycemic superiority in type 2 diabetes is similarly robust. SURPASS-2 showed HbA1c reductions of 2.30% with the highest tirzepatide trial arm vs 1.86% with the semaglutide comparator arm. The proportion reaching HbA1c normalization (below 5.7%) was approximately 52% with tirzepatide vs roughly 20% with semaglutide — a difference that goes beyond incremental improvement.

The side effect profiles are broadly similar. Both cause gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) that result from the shared GLP-1R mechanism of slowing gastric emptying. The boxed warning for medullary thyroid carcinoma risk applies to both. Specific rates differ somewhat — tirzepatide's nausea rate in SURMOUNT-1 approached 31-44% at higher trial-arm exposures, while semaglutide's STEP-1 trial reported approximately 44% nausea — but comparison across separate trials with different populations and escalation schedules should be made cautiously; only direct head-to-head data is fully reliable for safety comparisons.

The GIPR-specific effects of tirzepatide are thought to produce qualitative differences in adipose tissue metabolism and preservation of lean mass during weight loss compared with GLP-1 mono-agonists (mechanistic inference; preclinical/translational). Post-hoc body composition analyses suggest tirzepatide may produce proportionally greater fat mass loss relative to lean mass than semaglutide, but this finding requires confirmation in dedicated trials with DEXA or equivalent body composition endpoints.

Tirzepatide's safety profile is well-characterized by the SURPASS and SURMOUNT trial databases and post-marketing surveillance covering substantial post-approval use since 2022. Evidence tier for established adverse effects: strong (Phase 3 RCTs, FDA label, post-marketing data).

Gastrointestinal effects are the most common adverse events. Nausea (reported in roughly 20-31% of participants across doses in trial populations), diarrhea, vomiting, constipation, and abdominal pain result directly from the GLP-1-mediated slowing of gastric emptying. These effects are most prominent during the dose-escalation period and typically diminish over weeks as gastrointestinal adaptation occurs. They are the primary driver of treatment discontinuation in clinical trials, accounting for approximately 4-5% of discontinuations at the highest dose.

Pancreatitis carries a small but real signal. Clinical trial data showed a numerical imbalance favoring an increased pancreatitis rate compared with placebo (approximately 0.1-0.3% vs background rate). The FDA label carries a warning about pancreatitis. Any patient with a history of pancreatitis or significant alcohol use requires careful prescriber evaluation before initiating treatment.

Gallbladder disease (cholelithiasis and cholecystitis) occurs in roughly 2-3% of patients in long-term trials. This is primarily attributable to the effects of rapid significant weight loss on bile composition rather than a direct drug effect — gallstone formation increases with any rapid weight loss, pharmacological or otherwise. Patients with prior gallbladder history should discuss this risk with their prescriber.

A boxed warning covers medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia type 2 (MEN2). In rodent studies, GLP-1 receptor stimulation at clinically relevant exposures caused C-cell thyroid tumors. This has not been observed in human clinical trials or post-marketing surveillance with tirzepatide or other GLP-1 agents, but the mechanism is pharmacologically plausible, and these medications are contraindicated in patients with personal or family history of MTC or MEN2. This is the strongest absolute contraindication for the drug class.

Heart rate changes are common: a mean increase of 2-4 beats per minute from baseline is typical. Rare cases of first-degree atrioventricular block have been reported. Patients with pre-existing cardiac conduction abnormalities warrant monitoring.

Hypoglycemia in the absence of other glucose-lowering agents is uncommon because tirzepatide's insulin-secretory effects are glucose-dependent. However, when tirzepatide is used alongside insulin or sulfonylureas, the hypoglycemia risk from those agents increases due to enhanced glucose lowering, and prescriber-supervised dose adjustment of the concomitant agents is standard practice.

Eye examination findings of worsening diabetic retinopathy have been reported in some patients with pre-existing retinopathy during rapid glycemic improvement — a pattern also seen with other glucose-lowering therapies. Patients with known diabetic retinopathy should discuss ophthalmologic monitoring with their prescriber.

Renal function: Tirzepatide can cause acute kidney injury, primarily mediated through dehydration from GI side effects reducing fluid intake. Adequate hydration and caution in patients with pre-existing renal impairment are reflected in the label.

Several applications of tirzepatide beyond its two approved indications are under active clinical investigation. These are listed here to distinguish them clearly from approved uses — they are not current standard-of-care indications.

MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH): SURMOUNT-NASH trial data presented in 2024 showed histological improvement in liver fibrosis and MASH activity, with a meaningful proportion of tirzepatide-treated patients achieving MASH resolution without worsening fibrosis. This generated substantial clinical interest, but as of this writing, FDA approval specifically for MASH is not in place. Evidence tier: moderate (Phase 3 data available, regulatory submission in progress at the time of writing).

Heart failure with preserved ejection fraction (HFpEF): The SUMMIT trial enrolled adults with HFpEF and obesity. Tirzepatide produced improvements in exercise capacity, symptoms, and the composite heart failure outcome (cardiovascular death or worsening HF event) compared with placebo. Evidence tier: moderate (Phase 3 RCT, cardiac-specific endpoint data). FDA approval for this indication is not yet in place.

Polycystic ovary syndrome (PCOS): Phase 2 trial data suggests meaningful improvements in menstrual regularity, androgen levels, and metabolic markers in women with PCOS and obesity. Evidence tier: preliminary (Phase 2 data, no Phase 3 completion). Not an approved indication.

Cardiovascular morbidity and mortality in obesity without diabetes: The ongoing SURMOUNT-MMO trial is testing whether tirzepatide can reduce hard MACE endpoints in adults with obesity but without type 2 diabetes — a population not covered by the existing cardiovascular outcomes trial (which enrolled T2D patients). Results are not yet available.

All of these applications are being evaluated through the standard regulatory path. None should be considered approved uses, and prescribing for these conditions would be off-label use subject to the same prescriber judgment and risk-benefit evaluation required for any off-label application.